S Gastrointestinal And Liver Disease 12th: Edition
| Feature | Sleisenger & Fordtran (12th) | Yamada’s Textbook of Gastroenterology (7th) | Zakim & Boyer’s Hepatology (7th) | |--------|-------------------------------|-----------------------------------------------|-------------------------------------| | Focus | Full GI + Hepatology | Full GI + Hepatology | Hepatology only (but comprehensive) | | Style | Dense, encyclopedic | Slightly more narrative | Highly detailed liver-focused | | Best for | Board exam prep, clinical reference | Teaching, fellows’ reading | Hepatologists, liver transplant teams | | Images | Excellent (clinical + pathology) | Good | Superior liver histology and radiology | | Digital | Expert Consult (good) | Online access (comparable) | Included with print |
Given its size, the 12th edition can be intimidating. Here is a strategy for maximum utility:
The Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 12th Edition is available in multiple formats:
Review Question Book: Do not confuse the main textbook with Sleisenger and Fordtran's Gastrointestinal and Liver Disease Review, 12th Edition (sold separately). The review book contains over 1,000 board-style questions with detailed rationales—essential for exam preparation.
Unlike many review books that condense information into bullet points, Sleisenger and Fordtran offers depth. It does not merely state guidelines (e.g., "Administer drug X for condition Y"); it explains the pharmacokinetics, the clinical trial data behind the guideline, and the potential complications.
This edition is particularly praised for its balanced approach to evidence-based medicine. Where evidence is strong, the text is directive. Where evidence is lacking or controversial, the authors present the data neutrally, allowing the clinician to make informed decisions. s gastrointestinal and liver disease 12th edition
Question:
A 52-year-old with obesity, T2DM, and ALT 65 U/L undergoes MRI-PDFF showing 18% hepatic fat and F2 fibrosis by MRE. Which of the following is the most appropriate first-line pharmacotherapy according to the 12th edition guidelines?
A) Vitamin E 800 IU/day
B) Pioglitazone 45 mg/day
C) Resmetirom 80 mg/day
D) Semaglutide 1.0 mg/week
Answer: C (Resmetirom – first FDA-approved agent specifically for MASLD with fibrosis; vitamin E and pioglitazone are alternatives but not first-line per 2025–2026 guidelines)
If you need a specific chapter fully written (e.g., "MASLD" or "IBD medical therapy") in this style, or a comparison table between the 11th and 12th editions, let me know. This outline is ready for editorial submission or curriculum mapping.
For more than 50 years, Sleisenger and Fordtran's Gastrointestinal and Liver Disease | Feature | Sleisenger & Fordtran (12th) |
has remained the definitive reference for gastroenterology and hepatology professionals. The upcoming 12th Edition , scheduled for release in December 2025
, provides a comprehensive two-volume update on the pathophysiology, diagnosis, and management of GI and liver conditions. Key Features and Updates
The 12th edition is guided by a new senior editorial team including Drs. Raymond T. Chung, David T. Rubin, and C. Mel Wilcox . Major updates include: US Elsevier Health New Clinical Discussions
: Expanded coverage of eosinophilic disorders, autoimmune liver diseases, and the latest treatments for viral hepatitis. Renamed Conditions : Incorporation of new terminology, such as
(metabolic dysfunction-associated steatotic liver disease), formerly known as NAFLD. New Chapters Given its size, the 12th edition can be intimidating
: Dedicated sections on the gastrointestinal and hepatic manifestations of , as well as enterocolitis and hepatitis induced by cancer immunotherapy Advanced Technology : Updated insights into the use of AI in endoscopy for improved detection of GI cancers. Visual and Practical Aids : Over 1,100 full-color illustrations and more than 20 procedural videos
covering endoscopic techniques like balloon dilatation and stent placement. Reference Details Elsevier Health Sciences Publication Date 10–15 December 2025 978-0443116575 Page Count Approx. 2,500–3,700 pages (2-Volume Set) Target Audience
Gastroenterologists, hepatologists, residents, fellows, and medical students Availability and Pricing
The 12th edition is available for pre-order at several retailers: Elsevier Health : Offers the Complete 2-Volume Set for approximately ₹31,844 : Lists the hardcover 2-volume set at for ₹20,750. Specialized Medical Bookstores : Retailers like Naresh Book Store (₹20,485) and (₹20,999 ) offer pre-publication pricing. US Elsevier Health digital eBook access included with this edition?
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
Sleisenger and Fordtran's Gastrointestinal and Liver Disease
While maintaining its rigorous structure, the 12th edition introduces several significant updates: